A new review highlights SETDB1 as a key player in osteosarcoma, promoting tumor growth, immune evasion and therapy resistance. Blocking SETDB1 could enhance immunotherapy and chemotherapy ...

A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.” ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

New York Times reporter Jeremy Peters and Princeton University Professor Eddie Glaude join Chris Jansing to discuss President Trump expanding and defending Elon Musk’s power to make cuts to federal ...

A brave nine-year-old girl will have her leg amputated after a fall at after-school care led to a shocking diagnosis.

OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar ...

These funds are earmarked for finalizing the OST-HER2 osteosarcoma trial payments, manufacturing for FDA approval, and other operational costs, including the commercialization of the product.

OS Therapies, Inc., a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced that it received a Notice of Allowance from the United ...